Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors

Authors: Javier del Rey, Esther Prat, Immaculada Ponsa, Josep Lloreta, Antoni Gelabert, Ferran Algaba, Jordi Camps, Rosa Miró

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Aneuploidy, centrosome abnormalities and gene amplification are hallmarks of chromosome instability (CIN) in cancer. Yet there are no studies of the in vivo behavior of these phenomena within the same bladder tumor.

Methods

Twenty-one paraffin-embedded bladder tumors were analyzed by conventional comparative genome hybridization and fluorescence in situ hybridization (FISH) with a cyclin D1 gene (CCND1)/centromere 11 dual-color probe. Immunofluorescent staining of α, β and γ tubulin was also performed.

Results

Based on the CIN index, defined as the percentage of cells not displaying the modal number for chromosome 11, tumors were classified as CIN-negative and CIN-positive. Fourteen out of 21 tumors were considered CIN-positive. All T1G3 tumors were included in the CIN-positive group whereas the majority of Ta samples were classified as CIN-negative tumors. Centrosome clustering was observed in six out of 12 CIN-positive tumors analyzed. CCND1 amplification in homogeneously staining regions was present in six out of 14 CIN-positive tumors; three of them also showed amplification of this gene in double minutes.

Conclusions

Complex in vivo behavior of CCND1 amplicon in bladder tumor cells has been demonstrated by accurate FISH analysis on paraffin-embedded tumors. Positive correlation between high heterogeneity, centrosome abnormalities and CCND1 amplification was found in T1G3 bladder carcinomas. This is the first study to provide insights into the coexistence of CCND1 amplification in homogeneously staining regions and double minutes in primary bladder tumors. It is noteworthy that those patients whose tumors showed double minutes had a significantly shorter overall survival rate (p < 0.001).
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
3.
go back to reference Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, Miro R: Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology. 2001, 57: 986-992. 10.1016/S0090-4295(01)00909-8.CrossRefPubMed Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, Miro R: Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology. 2001, 57: 986-992. 10.1016/S0090-4295(01)00909-8.CrossRefPubMed
4.
go back to reference Bringuier PP, Tamimi Y, Schuuring E, Schalken J: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996, 12: 1747-1753.PubMed Bringuier PP, Tamimi Y, Schuuring E, Schalken J: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996, 12: 1747-1753.PubMed
5.
go back to reference Ewen ME, Lamb J: The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med. 2004, 10: 158-162. 10.1016/j.molmed.2004.02.005.CrossRefPubMed Ewen ME, Lamb J: The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med. 2004, 10: 158-162. 10.1016/j.molmed.2004.02.005.CrossRefPubMed
6.
go back to reference Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Hering F, et al: High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003, 201: 603-608. 10.1002/path.1481.CrossRefPubMed Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Hering F, et al: High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003, 201: 603-608. 10.1002/path.1481.CrossRefPubMed
7.
go back to reference Schwab M: Amplification of oncogenes in human cancer cells. Bioessays. 1998, 20: 473-479. 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N.CrossRefPubMed Schwab M: Amplification of oncogenes in human cancer cells. Bioessays. 1998, 20: 473-479. 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N.CrossRefPubMed
8.
go back to reference Roelofs H, Schuuring E, Wiegant J, Michalides R, Giphart-Gassler M: Amplification of the 11q13 region in human carcinoma cell lines: a mechanistic view. Genes Chromosomes Cancer. 1993, 7: 74-84. 10.1002/gcc.2870070203.CrossRefPubMed Roelofs H, Schuuring E, Wiegant J, Michalides R, Giphart-Gassler M: Amplification of the 11q13 region in human carcinoma cell lines: a mechanistic view. Genes Chromosomes Cancer. 1993, 7: 74-84. 10.1002/gcc.2870070203.CrossRefPubMed
9.
go back to reference Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE: Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006, 12: 5693-5697. 10.1158/1078-0432.CCR-06-1500.CrossRefPubMed Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE: Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006, 12: 5693-5697. 10.1158/1078-0432.CCR-06-1500.CrossRefPubMed
10.
go back to reference O'Neill S, Ekstrom L, Lastowska M, Roberts P, Brodeur GM, Kees UR, Schwab M, Bown N: MYCN amplification and 17q in neuroblastoma: evidence for structural association. Genes Chromosomes Cancer. 2001, 30: 87-90. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1055>3.0.CO;2-J.CrossRefPubMed O'Neill S, Ekstrom L, Lastowska M, Roberts P, Brodeur GM, Kees UR, Schwab M, Bown N: MYCN amplification and 17q in neuroblastoma: evidence for structural association. Genes Chromosomes Cancer. 2001, 30: 87-90. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1055>3.0.CO;2-J.CrossRefPubMed
11.
go back to reference Lengauer C: Aneuploidy and genetic instability in cancer. Semin Cancer Biol. 2005, 15: 1-10.1016/j.semcancer.2004.09.001.CrossRefPubMed Lengauer C: Aneuploidy and genetic instability in cancer. Semin Cancer Biol. 2005, 15: 1-10.1016/j.semcancer.2004.09.001.CrossRefPubMed
12.
13.
go back to reference Draviam VM, Xie S, Sorger PK: Chromosome segregation and genomic stability. Curr Opin Genet Dev. 2004, 14: 120-125. 10.1016/j.gde.2004.02.007.CrossRefPubMed Draviam VM, Xie S, Sorger PK: Chromosome segregation and genomic stability. Curr Opin Genet Dev. 2004, 14: 120-125. 10.1016/j.gde.2004.02.007.CrossRefPubMed
14.
go back to reference Andersen SS: Molecular characteristics of the centrosome. Int Rev Cytol. 1999, 187: 51-109. 10.1016/S0074-7696(08)62416-X.CrossRefPubMed Andersen SS: Molecular characteristics of the centrosome. Int Rev Cytol. 1999, 187: 51-109. 10.1016/S0074-7696(08)62416-X.CrossRefPubMed
15.
go back to reference Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ: Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998, 58: 3974-3985.PubMed Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ: Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998, 58: 3974-3985.PubMed
16.
go back to reference Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, Oga A, Naito K, Sasaki K: Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res. 2006, 12: 2752-2758. 10.1158/1078-0432.CCR-05-0805.CrossRefPubMed Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, Oga A, Naito K, Sasaki K: Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res. 2006, 12: 2752-2758. 10.1158/1078-0432.CCR-05-0805.CrossRefPubMed
17.
go back to reference Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, Raff JW: Centrosome amplification can initiate tumorigenesis in flies. Cell. 2008, 133: 1032-1042. 10.1016/j.cell.2008.05.039.CrossRefPubMedPubMedCentral Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, Raff JW: Centrosome amplification can initiate tumorigenesis in flies. Cell. 2008, 133: 1032-1042. 10.1016/j.cell.2008.05.039.CrossRefPubMedPubMedCentral
18.
go back to reference Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL: Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003, 106: 661-665. 10.1002/ijc.11251.CrossRefPubMed Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL: Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003, 106: 661-665. 10.1002/ijc.11251.CrossRefPubMed
19.
go back to reference Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, et al: Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res. 2004, 64: 4800-4809. 10.1158/0008-5472.CAN-03-3908.CrossRefPubMed Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, et al: Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res. 2004, 64: 4800-4809. 10.1158/0008-5472.CAN-03-3908.CrossRefPubMed
20.
go back to reference Kawamura K, Moriyama M, Shiba N, Ozaki M, Tanaka T, Nojima T, Fujikawa-Yamamoto K, Ikeda R, Suzuki K: Centrosome hyperamplification and chromosomal instability in bladder cancer. Eur Urol. 2003, 43: 505-515. 10.1016/S0302-2838(03)00056-3.CrossRefPubMed Kawamura K, Moriyama M, Shiba N, Ozaki M, Tanaka T, Nojima T, Fujikawa-Yamamoto K, Ikeda R, Suzuki K: Centrosome hyperamplification and chromosomal instability in bladder cancer. Eur Urol. 2003, 43: 505-515. 10.1016/S0302-2838(03)00056-3.CrossRefPubMed
21.
go back to reference Jin Y, Stewenius Y, Lindgren D, Frigyesi A, Calcagnile O, Jonson T, Edqvist A, Larsson N, Lundberg LM, Chebil G, et al: Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res. 2007, 13: 1703-1712. 10.1158/1078-0432.CCR-06-2705.CrossRefPubMed Jin Y, Stewenius Y, Lindgren D, Frigyesi A, Calcagnile O, Jonson T, Edqvist A, Larsson N, Lundberg LM, Chebil G, et al: Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res. 2007, 13: 1703-1712. 10.1158/1078-0432.CCR-06-2705.CrossRefPubMed
22.
go back to reference Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998, 22: 1435-1448. 10.1097/00000478-199812000-00001.CrossRefPubMed Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998, 22: 1435-1448. 10.1097/00000478-199812000-00001.CrossRefPubMed
23.
go back to reference Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H: Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res. 2003, 9: 2294-2299.PubMed Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H: Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res. 2003, 9: 2294-2299.PubMed
24.
go back to reference Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, Grignon DJ, Hostädter F, Lopez-Beltran A, Epstein JI: Non Invasive urothelial neoplasias. WHO classification of non invasive papillary urothelial tumors. World Health organisation classification of tumors. Pathology and gentics: tumors of the urinary sistem and male genital organs. Edited by: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 2004, Lyon: IARC Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, Grignon DJ, Hostädter F, Lopez-Beltran A, Epstein JI: Non Invasive urothelial neoplasias. WHO classification of non invasive papillary urothelial tumors. World Health organisation classification of tumors. Pathology and gentics: tumors of the urinary sistem and male genital organs. Edited by: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 2004, Lyon: IARC
25.
go back to reference Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW, Albrecht JH: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem. 2005, 280: 768-776.CrossRefPubMed Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW, Albrecht JH: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem. 2005, 280: 768-776.CrossRefPubMed
26.
go back to reference Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994, 10: 231-243. 10.1002/gcc.2870100403.CrossRefPubMed Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994, 10: 231-243. 10.1002/gcc.2870100403.CrossRefPubMed
27.
go back to reference Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS: Spindle multipolarity is prevented by centrosomal clustering. Science. 2005, 307: 127-129. 10.1126/science.1104905.CrossRefPubMed Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS: Spindle multipolarity is prevented by centrosomal clustering. Science. 2005, 307: 127-129. 10.1126/science.1104905.CrossRefPubMed
28.
go back to reference Chandhok NS, Pellman D: A little CIN may cost a lot: revisiting aneuploidy and cancer. Curr Opin Genet Dev. 2009, 19: 74-81. 10.1016/j.gde.2008.12.004.CrossRefPubMed Chandhok NS, Pellman D: A little CIN may cost a lot: revisiting aneuploidy and cancer. Curr Opin Genet Dev. 2009, 19: 74-81. 10.1016/j.gde.2008.12.004.CrossRefPubMed
30.
go back to reference Pihan GA, Wallace J, Zhou Y, Doxsey SJ: Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003, 63: 1398-1404.PubMed Pihan GA, Wallace J, Zhou Y, Doxsey SJ: Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003, 63: 1398-1404.PubMed
31.
go back to reference Thompson SL, Compton DA: Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol. 2008, 180: 665-672. 10.1083/jcb.200712029.CrossRefPubMedPubMedCentral Thompson SL, Compton DA: Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol. 2008, 180: 665-672. 10.1083/jcb.200712029.CrossRefPubMedPubMedCentral
32.
33.
go back to reference Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL: EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 1997, 15: 1617-1623. 10.1038/sj.onc.1201311.CrossRefPubMed Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL: EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 1997, 15: 1617-1623. 10.1038/sj.onc.1201311.CrossRefPubMed
34.
go back to reference Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003, 78: 323-335. 10.1023/A:1023033708204.CrossRefPubMed Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003, 78: 323-335. 10.1023/A:1023033708204.CrossRefPubMed
35.
go back to reference Jin C, Jin Y, Gisselsson D, Wennerberg J, Wah TS, Stromback B, Kwong YL, Mertens F: Molecular cytogenetic characterization of the 11q13 amplicon in head and neck squamous cell carcinoma. Cytogenet Genome Res. 2006, 115: 99-106. 10.1159/000095228.CrossRefPubMed Jin C, Jin Y, Gisselsson D, Wennerberg J, Wah TS, Stromback B, Kwong YL, Mertens F: Molecular cytogenetic characterization of the 11q13 amplicon in head and neck squamous cell carcinoma. Cytogenet Genome Res. 2006, 115: 99-106. 10.1159/000095228.CrossRefPubMed
36.
go back to reference Jin Y, Hoglund M, Jin C, Martins C, Wennerberg J, Akervall J, Mandahl N, Mitelman F, Mertens F: FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer. 1998, 22: 312-320. 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y.CrossRefPubMed Jin Y, Hoglund M, Jin C, Martins C, Wennerberg J, Akervall J, Mandahl N, Mitelman F, Mertens F: FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer. 1998, 22: 312-320. 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y.CrossRefPubMed
37.
go back to reference Debatisse M, Coquelle A, Toledo F, Buttin G: Gene amplification mechanisms: the role of fragile sites. Recent Results Cancer Res. 1998, 154: 216-226.CrossRefPubMed Debatisse M, Coquelle A, Toledo F, Buttin G: Gene amplification mechanisms: the role of fragile sites. Recent Results Cancer Res. 1998, 154: 216-226.CrossRefPubMed
38.
go back to reference Kuttler F, Mai S: Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. Semin Cancer Biol. 2007, 17: 56-64. 10.1016/j.semcancer.2006.10.007.CrossRefPubMed Kuttler F, Mai S: Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. Semin Cancer Biol. 2007, 17: 56-64. 10.1016/j.semcancer.2006.10.007.CrossRefPubMed
39.
go back to reference Narayanan V, Mieczkowski PA, Kim HM, Petes TD, Lobachev KS: The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. Cell. 2006, 125: 1283-1296. 10.1016/j.cell.2006.04.042.CrossRefPubMed Narayanan V, Mieczkowski PA, Kim HM, Petes TD, Lobachev KS: The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. Cell. 2006, 125: 1283-1296. 10.1016/j.cell.2006.04.042.CrossRefPubMed
40.
go back to reference Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL: Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA. 2000, 97: 7921-7926. 10.1073/pnas.130194897.CrossRefPubMedPubMedCentral Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL: Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA. 2000, 97: 7921-7926. 10.1073/pnas.130194897.CrossRefPubMedPubMedCentral
41.
go back to reference Morales C, Garcia MJ, Ribas M, Miro R, Munoz M, Caldas C, Peinado MA: Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol Cancer Ther. 2009, 8: 424-432. 10.1158/1535-7163.MCT-08-0759.CrossRefPubMed Morales C, Garcia MJ, Ribas M, Miro R, Munoz M, Caldas C, Peinado MA: Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol Cancer Ther. 2009, 8: 424-432. 10.1158/1535-7163.MCT-08-0759.CrossRefPubMed
42.
go back to reference Valent A, Benard J, Clausse B, Barrois M, Valteau-Couanet D, Terrier-Lacombe MJ, Spengler B, Bernheim A: In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol. 2001, 158: 1579-1584.CrossRefPubMedPubMedCentral Valent A, Benard J, Clausse B, Barrois M, Valteau-Couanet D, Terrier-Lacombe MJ, Spengler B, Bernheim A: In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol. 2001, 158: 1579-1584.CrossRefPubMedPubMedCentral
43.
go back to reference Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, Ho AD, Kramer A: Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res. 2007, 67: 6342-6350. 10.1158/0008-5472.CAN-07-0663.CrossRefPubMed Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, Ho AD, Kramer A: Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res. 2007, 67: 6342-6350. 10.1158/0008-5472.CAN-07-0663.CrossRefPubMed
Metadata
Title
Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors
Authors
Javier del Rey
Esther Prat
Immaculada Ponsa
Josep Lloreta
Antoni Gelabert
Ferran Algaba
Jordi Camps
Rosa Miró
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-280

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine